FDA says its safety review of abortion pill will continue into next year
The agency will compare mifepristone with surgical abortions and review side effects in about 100,000 women before issuing a final report.
- The Justice Department filed a court document Wednesday confirming The FDA expects to complete its safety review of the abortion pill mifepristone in March, responding to a federal judge in Louisiana's order for a progress report.
- Health Secretary Robert F. Kennedy Jr. commissioned the review last year after a conservative think tank alleged higher complication rates from mifepristone, though Researchers labeled those findings 'junk science' never peer-reviewed or published.
- The FDA will measure side effects among roughly 100,000 women, comparing mifepristone's safety to surgical abortions through 10 weeks of gestation in the comprehensive review.
- As a defendant in a Louisiana suit challenging telehealth access, the agency faces pressure from Republicans including Sen. Bill Cassidy, while nominee Heidi Overton sidestepped mifepristone safety questions at her confirmation hearing.
- The review's March completion date falls months after the Nov. 3 midterm elections, when abortion access remains among voters' key concerns, potentially influencing the political landscape around mifepristone access.
110 Articles
110 Articles
FDA Delays Review of Abortion Pill, Leaving Women Unprotected
The Food and Drug Administration (FDA) won’t complete its safety review of the dangerous abortion pill until later this year, and won’t release results until March 2027, a new filing from the Justice Department revealed. The U.S. Court of Appeals for the 5th Circuit ordered the FDA to file an update on its ongoing review […]
Catholic Review
The Catholic SunFDA expects to draft mifepristone safety review next year; pro-life groups call it 'insufficient'
The Food and Drug Administration's safety review of mifepristone is expected to stretch into next year, according to an Oct. 7 court filing, prompting disappointment from pro-life groups.
Ohio Capital Journal
Feds unlikely to change abortion pill policy before next year
The U.S. Food and Drug Administration said late Wednesday that it expects to complete its long-awaited safety review of abortion pills by mid-December and issue a report evaluating the results by March 2027. The agency disclosed the information in a court-mandated status report it submitted in the federal lawsuit Louisiana v. FDA. The timeline aligns […]
Coverage Details
Bias Distribution
- 42% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
